Whole genome sequencing has made visible what was always there but never measurable — the inherited risks that shape a family's health across generations. Legacy Genome exists to steward that knowledge with the gravity it demands.
For the entirety of human history, the genetic architecture of a family — its predispositions, its latent vulnerabilities, its silent carriers — has remained invisible. Families have watched patterns emerge across generations without explanation. A lineage of cardiac events. An inexplicable recurrence of early-onset disease. Conditions that seemed like fate because no instrument existed to read the code beneath them.
Whole genome sequencing has changed this permanently. For the first time, we possess the technology to read the complete genetic manuscript of a human life — not fragments, not approximations, but the full 3.2 billion base pairs that constitute a person's biological inheritance.
This is not an incremental advance. It is the emergence of an entirely new class of knowable risk — one that has never before achieved actuarial edification.
Until now, these risks have existed as specters — felt but unnamed, suspected but unquantifiable, passed down through bloodlines but never surfaced in any underwriting table or risk assessment. They have haunted families and confounded insurers alike, occupying a category of exposure that no financial instrument has been designed to address.
Legacy Genome recognizes this moment for what it is: not merely a commercial opportunity, but a threshold event — the point at which stewardship of genetic information becomes as essential to a family's legacy as stewardship of its financial assets.
Legacy Genome is not a technology platform that happens to involve genetics. It is a physician-led clinical practice that uses genomic technology as its instrument — guided by a founder who holds the rare intersection of medical licensure, genetic expertise, and the clinical judgment to interpret what the genome reveals.
In the concierge medicine model, the physician is the product. Clients are not purchasing software or a subscription to a platform — they are retaining a doctor whose clinical judgment, personal attention, and medical authority constitute the entirety of the value proposition.
This distinction is critical. Genome sequencing costs roughly $200 per person. The raw data is a commodity. What is not a commodity is the clinical interpretation — the physician who can translate 3.2 billion base pairs into actionable medical intelligence, communicate findings to families with appropriate gravity and nuance, and steward that knowledge across generations.
The $200 genome and the $100,000 interpretation. The value is not in the data — it is in the doctor.
Legacy Genome's founder recognized this asymmetry — that revolutionary technology had collapsed the cost of sequencing while leaving the clinical interpretation gap wide open — and built an institution to fill it. Not as a tech company, but as a medical practice with the intimacy of concierge care and the permanence of a trust.
Genome sequencing is not a medical test in the traditional sense. It is the complete digitization of a person's biological inheritance — a permanent, reanalyzable record that grows more valuable as science advances.
Unlike a blood panel or imaging study, which captures a single moment, a sequenced genome is time-agnostic. It can be interrogated today for known risks and reinterrogated tomorrow against discoveries that do not yet exist. Its value compounds indefinitely.
This is the fundamental insight: the genome is not a diagnostic — it is an asset. And like any sovereign asset, it requires custody, stewardship, and fiduciary-grade protection.
Genetic risks existed but could not be measured, priced, or managed. Families bore hidden exposure. Insurers underwrote in ignorance. Advisors had no tools to address biological risk.
23andMe and Ancestry offered fragments — entertainment-grade glimpses with no privacy, no actuarial value, and no fiduciary structure. Data was sold, not safeguarded.
Complete sequencing with physician-led interpretation, fiduciary stewardship, and private custody. Reanalyzable. Preserved across generations. Owned by the family — permanently.
The insurance industry prices risk based on what can be observed, measured, and historically modeled. But genetic risk has never fit this framework. It has always existed below the threshold of actuarial visibility — present in the biology, absent from the spreadsheet.
Consider what an underwriter sees today versus what the genome reveals:
The Genetic Information Nondiscrimination Act (GINA) of 2008 is the federal framework governing how genetic data can be used. It provides meaningful protections in employment and health insurance — but it contains critical exemptions that most families and their advisors do not fully understand.
These exemptions are not theoretical. They represent the precise categories of insurance where UHNW families carry the greatest financial exposure — and where genomic data is most actuarially relevant.
GINA prohibits the use of genetic information in health insurance underwriting and employment decisions. Employers and health insurers cannot request, require, or use genetic test results. This protection is well-established and federally enforced.
GINA explicitly does not apply to life insurance, disability insurance, or long-term care insurance. Insurers in these categories can legally request and use genetic information in underwriting. For families carrying $10M+ in coverage, this represents substantial unmanaged exposure.
This regulatory asymmetry creates both a risk and an opportunity. Families who sequence proactively — with physician-guided interpretation and private custody outside insurer-accessible systems — can control the narrative of their genetic data rather than having it discovered in contexts that may be disadvantageous.
Legacy Genome's architecture is built around this reality. Genomic data is held in HIPAA-compliant encrypted storage, outside of EMR and insurer databases, accessible only through the physician-patient relationship. The family controls what is disclosed, when, and to whom.
Despite the maturation of genomic technology, no company provides proactive, private, physician-led genomic stewardship for families seeking prevention, assurance, and legacy preservation.
23andMe, Ancestry — entertainment with zero privacy guarantees, no actuarial value, and data routinely sold to third parties. Recently bankrupt, proving the model's fragility.
Hospital-based genetic services exist for the already ill. Insurance-gated, embedded in EMR systems, and structurally incapable of proactive, multi-generational stewardship.
Executive health is comprehensive but non-genomic. Wealth advisors manage every asset class except biology. No physician-led institution serves as a genetic trustee. Legacy Genome fills this void.
Legacy Genome did not pursue this opportunity out of commercial ambition alone. We arrived at it through a recognition that, once understood, could not be set aside.
The technology now exists to protect families from risks that have persisted — unnamed and unmanaged — across every prior generation. The strategies for wealth preservation, risk mitigation, and proactive generational security are time-agnostic: they do not depend on when a family acts, only that it acts. The genome sequenced today serves grandchildren not yet born.
To recognize this capacity and fail to build the institution that exercises it would be a dereliction — not of business, but of purpose.
Legacy Genome is pioneering a new fiduciary discipline: the long-term, intergenerational stewardship of genetic knowledge as a cornerstone of family legacy. We exist because the message within the genome — once decoded — self-evidently decrees the duty to protect it.
Families don't buy tests. They retain a physician-geneticist as a Genetic Trustee — with services structured like trust administration and concierge medicine, not healthcare transactions.
Secure, encrypted genomic vault — owned by the family, outside EMR and insurer systems. Protected with the same gravity as financial assets held in trust. Private by architecture, not policy.
Physician-led clinical interpretation of whole genome data. Actionable findings communicated with medical authority and personal attention. The $200 genome meets the six-figure analysis.
Ongoing reanalysis against emerging science, intergenerational onboarding, and permanent stewardship. A living inheritance whose value compounds as genomic knowledge advances.
Families with $10M+ routinely pay substantial life insurance premiums against risks that are, in part, genetic in origin — yet those genetic risks have never been visible to underwriters.
Negative predictive value — a genome sequenced with no clinically actionable pathogenic variants — provides a powerful signal. It does not guarantee health, but it meaningfully reduces the probability space of the conditions that drive the largest insurance claims.
The insurance industry has not yet built the frameworks to price this information. Legacy Genome is working to build that bridge — and early-mover families stand to benefit most when it is complete.
Pricing reflects the physician's time, clinical interpretation complexity, and ongoing stewardship commitment. It scales with the family's needs and the maturity of the actuarial validation.
Revenue model mirrors concierge medicine — annual retainers with strong retention. We present three scenarios reflecting different market reception and actuarial validation timelines.
Privacy outside EMR and insurer systems. Physician-led interpretation by a board-certified geneticist. Genomic data preserved like financial inheritance. Knowledge that protects generations.
A differentiated offering that addresses biological risk — the one asset class no other advisor can touch. Deeper client relationships and a stickier, higher-value practice.
Improved underwriting accuracy on previously invisible risk. Lower claims through proactive management. Actuarial clarity on the last major class of unpriced exposure.
First-mover in an unclaimed category. Physician-led model with concierge-medicine economics. Low startup capital requirement with high-margin, recurring revenue potential.
Legacy Genome is selectively engaging investors, family office networks, and insurance partners aligned with the long-term stewardship of genetic legacy.
Request Investor Materials